etentamig

News

AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.